An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

NCT00001757 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

20

Enrollment

NIH

Sponsor class

Conditions

Mycoses

Interventions

DRUG: Voriconazole

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)